专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

71. 发明申请

US20100196414A1 Silver Ionized Plant Extraction Liquid and Use Thereof 有权
标题翻译：银离子植物提取液及其用途
公开(公告)号：US20100196414A1
公开(公告)日：2010-08-05
申请号：US12762286
申请日：2010-04-16
申请人： Dong-gyu Bai , Jeong-ho Lee , Kyu-jeong Cho , Sun-mi Huh , Sang-hwa Park
发明人： Dong-gyu Bai , Jeong-ho Lee , Kyu-jeong Cho , Sun-mi Huh , Sang-hwa Park
IPC分类号： A01N65/03 , A01N65/00 , A01N65/44 , A01N65/08 , A01N65/06 , A01P1/00
CPC分类号： A61K36/14 , A61K33/38 , A61K36/02 , A61K36/15 , A61K36/49 , A61K36/899 , Y02A50/471 , Y02A50/481 , Y02A50/483 , A61K2300/00
摘要： The present invention relates to silver-ionized plant extraction liquid and the use thereof. Particularly, there are provided herein a silver-ionized liquid extraction liquid prepared by ionizing silver in a plant extraction liquid used as an electrolyte and an antimicrobial composition comprising the same.
摘要翻译：本发明涉及银离子植物提取液及其用途。特别地，本文提供了通过使用作为电解质的植物提取液中的银进行电离而制备的银离子液体提取液和包含该电解质的抗微生物组合物。

72. 发明申请

US20090176866A1 Complexes having adjuvant activity 审中-公开
标题翻译：具有佐剂活性的复合物
公开(公告)号：US20090176866A1
公开(公告)日：2009-07-09
申请号：US10585286
申请日：2005-01-07
申请人： Sunil Shaunak , Stephen Brocchini , Antony Godwin , Ji-Won Choi
发明人： Sunil Shaunak , Stephen Brocchini , Antony Godwin , Ji-Won Choi
IPC分类号： A61K31/365
CPC分类号： A61K45/06 , A61K31/7048 , A61K31/78 , Y02A50/387 , Y02A50/409 , Y02A50/411 , Y02A50/414 , Y02A50/415 , Y02A50/423 , Y02A50/463 , Y02A50/465 , Y02A50/471 , Y02A50/481 , Y02A50/483
摘要： A complex that comprises a narrow molecular weight distribution polymer that includes units derived from an acrylic acid or a salt thereof, and (i) a substance that has pharmacological activity against a pathogenic organism, or (ii) a substance that has pharmacological activity against a cancer, or (iii) one or more agents selected from antigens and immunogens is useful in treating and/or inducing immunity to the pathogenic organism or the cancer, and for inducing immunity to the antigen or immunogen.
摘要翻译：一种复合物，其包含窄分子量分布聚合物，其包含衍生自丙烯酸或其盐的单元，和（i）对致病性生物体具有药理活性的物质，或（ii）具有针对病原体的药理活性的物质癌症，或（iii）选自抗原和免疫原的一种或多种药物可用于治疗和/或诱导对致病生物体或癌症的免疫，以及诱导对抗原或免疫原的免疫。

73. 发明授权

US07547726B2 AI-2 compounds and analogs based on Salmonella typhimurium LsrB structure 失效
标题翻译：基于鼠伤寒沙门氏菌LsrB结构的AI-2化合物和类似物
公开(公告)号：US07547726B2
公开(公告)日：2009-06-16
申请号：US11228707
申请日：2005-09-16
申请人： Stephen T. Miller , Karina B. Xavier , Michiko E. Taga , Shawn R. Campagna , Martin F. Semmelhack , Bonnie L. Bassler , Frederick M. Hughson
发明人： Stephen T. Miller , Karina B. Xavier , Michiko E. Taga , Shawn R. Campagna , Martin F. Semmelhack , Bonnie L. Bassler , Frederick M. Hughson
IPC分类号： A61K31/341
CPC分类号： C07H7/02 , A61K38/00 , C07H3/02 , C07K14/255 , C07K2299/00 , Y02A50/47 , Y02A50/471 , Y02A50/473 , Y02A50/481 , Y02A50/483
摘要： This invention relates to crystals comprising apo-LsrB and holo-LsrB. The structure of holo-LsrB identifies a tetrahydroxytetrahydrofuran derived from 4,5-dihydroxy-2,3-pentanedione (DPD) as the active autoinducer-2 (AI-2) molecule in Salmonella typhimurium. The X-ray crystallographic data can be used in a drug discovery method. Additionally the invention provides AI-2 analogs based on this discovery as well as pharmaceutical compositions containing those analogs.
摘要翻译：本发明涉及包含apo-LsrB和holo-LsrB的晶体。全LsrB的结构鉴定了来自4,5-二羟基-2,3-戊二酮（DPD）的四羟基四氢呋喃作为鼠伤寒沙门氏菌中的活性自动诱导剂-2（AI-2）分子。 X射线晶体学数据可用于药物发现方法。另外本发明提供了基于该发现的AI-2类似物以及含有这些类似物的药物组合物。

74. 发明授权

US07504381B2 Antimicrobial agents 失效
标题翻译：抗微生物剂
公开(公告)号：US07504381B2
公开(公告)日：2009-03-17
申请号：US11234183
申请日：2005-09-26
申请人： Amram Mor , Inna Radzishevsky
发明人： Amram Mor , Inna Radzishevsky
IPC分类号： A61K38/08 , A61K38/10 , C07K7/06 , C07K7/08
CPC分类号： A61K38/02 , A23L3/3481 , A23L3/3526 , A61K31/74 , A61K47/542 , A61K49/0002 , A61M15/00 , C07K7/06 , C07K7/08 , C07K14/001 , C07K14/4723 , Y02A50/401 , Y02A50/411 , Y02A50/471 , Y02A50/473 , Y02A50/48 , Y02A50/483
摘要： A novel class of antimicrobial polymeric agents, which include a plurality of amino acid residues, such as positively charged amino acid residues, and at least one hydrophobic residue linking there between. such as an omega-amino-fatty acid residue designed to exert antimicrobial activity while being stable, non-toxic and avoiding development of resistance thereto and a process of preparing same are disclosed. Further disclosed are pharmaceutical compositions containing same and a method of treating medical conditions associated with pathological microorganisms, a medical device, an imaging probe and a food preservative utilizing same. Further disclosed are conjugates of an amino acid residue and a hydrophobic moiety residue and a process of preparing same.
摘要翻译：一类新的抗微生物聚合物，其包括多个氨基酸残基，例如带正电荷的氨基酸残基，以及至少一个在其间连接的疏水性残基。例如设计为在稳定，无毒和避免耐药性的同时发挥抗微生物活性的ω-氨基 - 脂肪酸残基及其制备方法。进一步公开的是包含其的药物组合物和治疗与病理性微生物相关的医学病症的方法，医疗装置，成像探针和利用其的食品防腐剂。进一步公开的是氨基酸残基和疏水部分残基的缀合物及其制备方法。

75. 发明申请

US20080188403A1 Parenteral Combination Therapy For Infective Conditions With Drug Resistant Bacterium 有权
标题翻译：肠胃外联合治疗用于耐药细菌的感染条件
公开(公告)号：US20080188403A1
公开(公告)日：2008-08-07
申请号：US11816179
申请日：2006-02-08
申请人： Manu Chaudhary
发明人： Manu Chaudhary
IPC分类号： A61K38/14
CPC分类号： A61K45/06 , A61K31/546 , Y02A50/401 , Y02A50/402 , Y02A50/406 , Y02A50/471 , Y02A50/473 , Y02A50/475 , Y02A50/478 , Y02A50/479 , Y02A50/481 , Y02A50/483 , A61K2300/00
摘要： The invention describes a pharmaceutical composition to combat multiple-drug-resistant bacteria in non-ocular infective conditions. Compositions comprising glycopeptides, in particular vancomycin, and cephalosporins, in particular ceftriaxone, are disclosed. Such compositions are found to be useful for parenteral administration for hospitalized patients with serious infections. Specifically, this invention also discloses a pharmaceutical composition further including an excipient such as CVMC agent and is available in dry powder form for reconstitution before injection with a suitable solvent. The pharmaceutical compositions of this invention have been found normally to enhance resistance to precipitation in solutions to be administered parenterally. The invention also gives details of the dosage forms stored in sealed containers to be reconstituted before use. The invention further provides a process to manufacture these compositions and also a method of treating a subject having non-ocular infective conditions due to multi drug resistant bacterium.
摘要翻译：本发明描述了用于在非眼部感染性病症中对抗多重耐药细菌的药物组合物。公开了包含糖肽，特别是万古霉素和头孢菌素，特别是头孢曲松的组合物。发现这种组合物对于严重感染的住院患者的肠胃外给药是有用的。具体地说，本发明还公开了一种药物组合物，其进一步包括赋形剂如CVMC剂，并且可以以干粉形式获得，以在注射之前用合适的溶剂进行重新配制。已经发现本发明的药物组合物通常用于增强肠胃外给药的溶液中的沉淀抗性。本发明还提供储存在使用前重新配制的密封容器中的剂型的细节。本发明还提供了制造这些组合物的方法，还提供了一种治疗由于多药耐药细菌引起的非眼部感染病症的受试者的方法。

76. 发明申请

US20080113918A1 AGONIST POLYPEPTIDE OF RECEPTOR FOR ZOT AND ZONULIN 审中-公开
标题翻译： ZOT和ZONULIN受体的激素多肽
公开(公告)号：US20080113918A1
公开(公告)日：2008-05-15
申请号：US11933132
申请日：2007-10-31
申请人： Alessio Fasano , Stefanie N. Vogel
发明人： Alessio Fasano , Stefanie N. Vogel
IPC分类号： A61K38/00 , C07K7/00 , A61P43/00
CPC分类号： C07K14/28 , A61K38/00 , C07K7/06 , G01N33/564 , Y02A50/471 , Y02A50/473 , Y02A50/483
摘要： Agonist polypeptide of a receptor protein has been identified. The agonist can be used to facilitate drug and antigen absorption. Suitable routes of administration include oral, nasal, transdermal, and intravenous. Pharmaceutical formulations may comprise a therapeutic agent or an immunogenic agent in combination with the agonist polypeptide.
摘要翻译：已经鉴定了受体蛋白质的激动剂多肽。激动剂可用于促进药物和抗原吸收。合适的给药途径包括口服，鼻腔，经皮和静脉内。药物制剂可以包含与激动剂多肽组合的治疗剂或免疫原性试剂。

77. 发明申请

US20060281684A1 Polymyxin B analogs for LPS detoxification 失效
标题翻译：多粘菌素B类似物用于LPS解毒
公开(公告)号：US20060281684A1
公开(公告)日：2006-12-14
申请号：US11398915
申请日：2006-04-06
申请人： Massimo Porro , Massimo Velucchi , Alessandro Rustici , Monique Moreau , Noelle Mistretta , Tino Krell
发明人： Massimo Porro , Massimo Velucchi , Alessandro Rustici , Monique Moreau , Noelle Mistretta , Tino Krell
IPC分类号： A61K38/10 , A61K38/08 , C07K7/08 , C07K7/06
CPC分类号： C07K7/08 , A61K38/00 , C07K7/06 , C07K7/54 , Y02A50/471 , Y02A50/473 , Y02A50/475 , Y02A50/478 , Y02A50/481 , Y02A50/483
摘要： The invention relates to SAEP II peptide dimers that mimic polymyxin B i.a. in its ability to bind non-covalently the lipopolysaccharide (LPS) of Gram-negative bacteria with high affinity, and therefore to detoxify LPS as polymyxin B does. The dimeric structure is maintained by a pair of disulphide bonds involving the two cystein residues present in the peptide sequence, which does not exceed 17 amino acids and essentially comprises cationic and hydrophobic amino acid residues. In the dimers of the invention, peptides may have a parallel or anti-parallel orientation. As a matter of example, a dimer of the invention is constituted by a peptide of formula NH2-Lys-Thr-Lys-Cysl-Lys-Phe-Leu-Leu-Leu-Cys2-COOH, either in a parallel or antiparallel dimeric form. SAEP II dimers are useful for treating or preventing septic shock and related disorders generated by Gram-negative bacteria infection. The invention also relates to LPS-peptide complexes in which LPS and SAEP II diners are non-covalently bound together. These complexes are useful as vaccinal agents against Gram-negative bacteria infection.
摘要翻译：本发明涉及模拟多粘菌素B i.a.的SAEP II肽二聚体。在其以高亲和力非共价结合革兰氏阴性细菌的脂多糖（LPS）的能力，因此使LPS作为多粘菌素B解毒。二聚体结构通过涉及肽序列中存在的两个半胱氨酸残基的一对二硫键来维持，其不超过17个氨基酸并且基本上包含阳离子和疏水氨基酸残基。在本发明的二聚体中，肽可以具有平行或反平行取向。作为实例，本发明的二聚体由式NH2-Lys-Thr-Lys-Cys1-Lys-Phe-Leu-Leu-Leu-Leu-Cys2-COOH的肽构成，以平行或反向平行的二聚体形式。 SAEP II二聚体可用于治疗或预防由革兰氏阴性菌感染引起的败血性休克和相关疾病。本发明还涉及其中LPS和SAEP II食用者非共价结合在一起的LPS-肽复合物。这些复合物可用作抗革兰氏阴性菌感染的疫苗。

78. 发明申请

US20060276473A1 Use and administration of bacterial efflux pump inhibitors 失效
标题翻译：使用和管理细菌外排泵抑制剂
公开(公告)号：US20060276473A1
公开(公告)日：2006-12-07
申请号：US11082745
申请日：2005-03-16
申请人： Keith Bostion , Tomasz Glinka , Olga Lomovskaya , Mark Surber
发明人： Keith Bostion , Tomasz Glinka , Olga Lomovskaya , Mark Surber
IPC分类号： A61K31/53 , A61K31/506 , A61K31/501 , A61K31/497 , A61K31/4439 , A61K31/433 , A61K31/427 , A61K31/4245 , A61K31/421
CPC分类号： A61K45/06 , A61K31/00 , A61K31/135 , A61K31/421 , A61K31/4245 , A61K31/427 , A61K31/433 , A61K31/4439 , A61K31/497 , A61K31/501 , A61K31/506 , A61K31/53 , Y02A50/401 , Y02A50/47 , Y02A50/471 , Y02A50/473 , Y02A50/475 , Y02A50/478 , Y02A50/481 , Y02A50/483 , A61K2300/00
摘要： This invention provides for efflux pump inhibitors to be co-administered with antimicrobial agents for the treatment of infections caused by drug resistant pathogens, novel efflux pump inhibitors, combined dosage forms of efflux pump inhibitors with an antimicrobial, and novel medical methods.
摘要翻译：本发明提供了与抗微生物剂共同施用的外排泵抑制剂，用于治疗由耐药性病原体引起的感染，新型外排泵抑制剂，具有抗微生物剂的外排泵抑制剂的组合剂型和新颖的医学方法。

79. 发明申请

US20060251663A1 Employment of rotavirus proteins, derived proteins and peptides for the modulation of tisssue permeability 有权
标题翻译：轮状病毒蛋白质，衍生蛋白质和肽用于调节组织渗透性
公开(公告)号：US20060251663A1
公开(公告)日：2006-11-09
申请号：US10540843
申请日：2003-01-10
申请人： Lorenza Mariscal-Gonzalez , Porfirio Nava-Dominguez
发明人： Lorenza Mariscal-Gonzalez , Porfirio Nava-Dominguez
IPC分类号： A61K38/28 , C12Q1/70 , A61K39/42 , C07H21/04 , A61K31/704 , A61K31/43 , A61K39/15 , C07K14/005 , C07K16/10
CPC分类号： C07K14/005 , A61K38/162 , A61K47/42 , C07K2319/00 , C12N2720/12322 , Y02A50/471 , Y02A50/475 , Y02A50/483
摘要： The present invetnion refers to the use of rotavirus proteins VP4, VP8 and their derived fusion proteins and peptides, for enhancing the delivery of pharmaceutical agents through the paracellular pathway. These rotavirus proteins and derived peptides may additionally be employed to reduce unwanted cellular adhesion that can occur between cancerous cells, or between normal cells as a result of surgery, injury, chemotherapy, disease, inflammation or other pathological conditions.
摘要翻译：本发明是指使用轮状病毒蛋白VP4，VP8及其衍生的融合蛋白和肽来增强药剂通过旁分泌途径的递送。另外可以使用这些轮状病毒蛋白质和衍生肽，以减少由于手术，损伤，化疗，疾病，炎症或其它病理状况而导致癌细胞之间或正常细胞之间发生的不必要的细胞粘附。

80. 发明申请

US20060229259A1 AI-2 compounds and analogs based on Salmonella typhimurium LsrB structure 审中-公开
公开(公告)号：US20060229259A1
公开(公告)日：2006-10-12
申请号：US11104681
申请日：2005-04-12
申请人： Stephen Miller , Karina Xavier , Mlchiko Taga , Shawn Campagna , Martin Semmelhack , Bonnie Bassler , Frederick Hughson
发明人： Stephen Miller , Karina Xavier , Mlchiko Taga , Shawn Campagna , Martin Semmelhack , Bonnie Bassler , Frederick Hughson
IPC分类号： G06F19/00 , A61K31/70 , C07K14/255
CPC分类号： C07H7/02 , A61K38/00 , C07H3/02 , C07K14/255 , C07K2299/00 , Y02A50/47 , Y02A50/471 , Y02A50/473 , Y02A50/481 , Y02A50/483
摘要： This invention relates to crystals comprising apo-LsrB and holo-LsrB. The structure of holo-LsrB identifies a tetrahydroxytetrahydrofuran derived from 4,5-dihydroxy-2,3-pentanedione (DPD) as the active autoinducer-2 (AI-2) molecule in Salmonella typhimurium. The X-ray crystallographic data can be used in a drug discovery method. Additionally the invention provides AI-2 analogs based on this discovery as well as pharmaceutical compositions containing those analogs.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式